Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
the inspection conducted from January 27 to January 31, 2025
The inspection was carried out from January 28 to February 1, 2025
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated